We know that there are urgent questions about which groups would benefit from more intensive treatment, and so Hypertension Canada has set out to provide you with the best guidance as quickly as possible. Three of our CHEP Guidelines Committee subgroups (Pharmacotherapy for Hypertensive Patients Without Compelling Indications, Cardiovascular Risk Assessment, and Renal and Renovascular Hypertension) are currently reviewing the data.
The subgroups will independently report initial findings for discussion with the Central Review Committee by late December. At that time, we will determine what steps are required to achieve clarity and alignment. eINFO subscribers will be the first to receive updates, so please be sure to sign up if you have not already done so and feel free to forward this email to anyone who may be interested.
In the interim, Hypertension Canada encourages health care professionals to adhere to existing guidelines. Practitioners can also discuss the results of this study - the risks and benefits of intensive hypertension treatment - with their patients, involving them as partners in decisions about their health care.
Looking forward to updating you soon! Sincerely,
|
| Dr. Ernesto Schiffrin, C.M., MD, PhD, FRSC, FRCPC, FACP President, Hypertension Canada | Dr. Doreen Rabi, MD, FRCPC, MSc Co-Chair, CHEP Guidelines |
|